vor 2 Jahren

DGAP-News: Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara®* in Phase III Study

DGAP-News: Formycon AG / Key word(s): Study results/Study
Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara®* in Phase III Study

16.08.2022 / 07:30 CET/CEST
The issuer is solely...

Quelle: Börse Online RSS Feed

I saw this ad on X. And I took it personally!vor 3 Stunden
Let's do a stress test and see what happens. Withdraw all your Bitcoin from Coinbase!vor 4 Stunden
The Bitcoin ETFs have purchased $100,000,000 worth of Bitcoin PER TRADING DAY on average since January 11thvor 4 Stunden
Amauri: With BCH You Have Gold In Your Handsvor 4 Stunden
No 1 on localcoinswap sellingvor 5 Stunden
Free Trading Software: Legal and Ethical Questionsvor 5 Stunden
Is there any vault kind of thing where I can store my crypto in INDIA, instead of buying them in exchanges like CoinDCXvor 6 Stunden
Why Bitcoin Is Superior To Real Estate (12 Reasons)vor 7 Stunden
Bitwarden vs Proton vs KeePassvor 7 Stunden
Edelcoin: Eine Kryptowährung gedeckt durch Industriemetallevor 7 Stunden

DGAP-News: Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara&#174;* in Phase III Study

DGAP-News: Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara®* in Phase III Study